Furthermore, greater BARD1 expression associated with worse patient outcome across multiple cancer types (Figures 6D and S4B), as observed across the entire TCGA pan-cancer cohort (n = 10,152 patients, correcting for survival differences by cancer type cancer type),37 as well as for individual cancer types, including breast cancer (n = 1,302)38 and bladder cancer (n = 1,035),24 representing other patient cohorts. This evidence concerns the gene BARD1 and breast cancer.